Nicola Rocco, Matteo Ghilli, Annalisa Curcio, Marina Bortul, Stefano Burlizzi, Carlo Cabula, Roberta Cabula, Alberta Ferrari, Secondo Folli, Lucio Fortunato, Patrizia Frittelli, Oreste Gentilini, Sara Grendele, Massimo Maria Grassi, Simona Grossi, Francesca Magnoni, Roberto Murgo, Dante Palli, Francesca Rovera, Alessandro Sanguinetti, Mario Taffurelli, Giovanni Tazzioli, Daniela Andreina Terribile, Francesco Caruso, Viviana Galimberti
BACKGROUND: De-escalation of axillary surgery in breast cancer (BC) management began when sentinel lymph node biopsy (SLNB) replaced axillary lymph node dissection (ALND) as standard of care in patients with node-negative BC. The second step consolidated ALND omission in selected subgroups of BC patients with up to two macrometastases and recognized BC molecular and genomic implication in predicting prognosis and planning adjuvant treatment. Outcomes from the recent RxPONDER and monarchE trials have come to challenge the previous cut-off of two SLN in order to inform decisions on systemic therapies for hormone receptor-positive (HR+), human epidermal growth factor receptor type-2 (HER2) negative BC, as the criteria included a cut-off of respectively three and four SLNs...
January 6, 2024: European Journal of Surgical Oncology